Evidence map›Paper›PMID 42256676›Full record

ReviewEClinicalMedicine2026

Weight maintenance after discontinuation of GLP-1 therapies.

Areesha Moiz, Kristian B Filion, Bärbel Knäuper, Michael A Tsoukas, Anne-Sophie Brazeau, Tetiana Zolotarova, Audrey Lelièvre, Mark J Eisenberg

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Weight management in cardiology practice: challenges and opportunities.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Areesha MoizCentre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital/McGill University, Montreal, QC, Canada.
Kristian B FilionCentre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital/McGill University, Montreal, QC, Canada.
Bärbel KnäuperDepartment of Psychology, McGill University, Montreal, QC, Canada.
Michael A TsoukasDivision of Endocrinology, McGill University Health Centre, Montreal, QC, Canada.
Anne-Sophie BrazeauSchool of Human Nutrition, McGill University, Montreal, QC, Canada.
Tetiana ZolotarovaCentre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital/McGill University, Montreal, QC, Canada.
Audrey LelièvreCentre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital/McGill University, Montreal, QC, Canada.
Mark J EisenbergCentre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital/McGill University, Montreal, QC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual/triple co-agonists have revolutionized obesity treatment, producing mean weight losses of 10-30% that were rarely achievable with lifestyle modification or earlier medications. Yet, once GLP-1 therapy is discontinued, most patients experience rapid weight regain, often accompanied by reversal of cardiometabolic improvements. Real-world data show that up to 65% of users discontinue GLP-1 RAs within a year of initiation, and randomized controlled trials demonstrate that two-thirds of lost weight is typically regained within a year of discontinuation. Weight regain following GLP-1 RA discontinuation reflects a powerful interplay of physiological, behavioral, and environmental factors that promote relapse once pharmacological appetite suppression is removed. Sustaining weight loss after GLP-1 RA discontinuation will ultimately depend on integrated, patient-centered frameworks combining ongoing lifestyle, behavioral, and system-level supports.

Indexed as

Glucagon-like peptide-1 receptor agonistMaintenancePharmacotherapy discontinuationWeight cyclingWeight rebound

Identifiers

PMID42256676
PMCPMC13240724

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.